CN114106099B - 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 - Google Patents

蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 Download PDF

Info

Publication number
CN114106099B
CN114106099B CN202111432527.8A CN202111432527A CN114106099B CN 114106099 B CN114106099 B CN 114106099B CN 202111432527 A CN202111432527 A CN 202111432527A CN 114106099 B CN114106099 B CN 114106099B
Authority
CN
China
Prior art keywords
seq
amino acid
antibody
acid sequence
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111432527.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114106099A (zh
Inventor
S.J.穆尔
M.T.L.阮
D.R.霍斯特特
O.瓦西列瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomx Therapeutics Inc
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Priority to CN202111432527.8A priority Critical patent/CN114106099B/zh
Publication of CN114106099A publication Critical patent/CN114106099A/zh
Application granted granted Critical
Publication of CN114106099B publication Critical patent/CN114106099B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202111432527.8A 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法 Active CN114106099B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111432527.8A CN114106099B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461934619P 2014-01-31 2014-01-31
US61/934619 2014-01-31
US201461971009P 2014-03-27 2014-03-27
US61/971009 2014-03-27
CN201580016781.6A CN106459153B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
PCT/US2015/013776 WO2015116933A2 (en) 2014-01-31 2015-01-30 Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CN202111432527.8A CN114106099B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580016781.6A Division CN106459153B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法

Publications (2)

Publication Number Publication Date
CN114106099A CN114106099A (zh) 2022-03-01
CN114106099B true CN114106099B (zh) 2024-05-24

Family

ID=52484571

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111432527.8A Active CN114106099B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
CN201580016781.6A Active CN106459153B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580016781.6A Active CN106459153B (zh) 2014-01-31 2015-01-30 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法

Country Status (14)

Country Link
US (5) US9562073B2 (enExample)
EP (3) EP3628328B1 (enExample)
JP (3) JP6835586B2 (enExample)
KR (1) KR102466591B1 (enExample)
CN (2) CN114106099B (enExample)
AU (3) AU2015210862B2 (enExample)
BR (1) BR112016017649B1 (enExample)
DK (1) DK3628328T3 (enExample)
ES (1) ES2932777T3 (enExample)
IL (5) IL294782B2 (enExample)
NZ (1) NZ722401A (enExample)
RU (1) RU2016135239A (enExample)
WO (1) WO2015116933A2 (enExample)
ZA (1) ZA202208159B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
BR112016001611B1 (pt) * 2013-07-25 2024-01-09 Cytomx Therapeutics, Inc Anticorpo ativável multiespecífico, uso terapêutico do mesmo, molécula de ácido nucleico isolada, vetor e método para produzir um anticorpo ativável multiespecífico
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2016182064A1 (ja) 2015-05-13 2016-11-17 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
SG10202101909RA (en) 2015-08-07 2021-04-29 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
BR102016018074A2 (pt) * 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CN106519037B (zh) * 2015-09-11 2019-07-23 科济生物医药（上海）有限公司 可活化的嵌合受体
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11225520B2 (en) 2016-02-16 2022-01-18 Dana-Farber Cancer Institute, Inc. Immunotherapy compositions and methods
KR20230073346A (ko) 2016-11-28 2023-05-25 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
EP3551667A4 (en) 2016-12-09 2020-06-17 Seattle Genetics, Inc. Bivalent antibodies masked by coiled coils
KR20240165484A (ko) 2017-04-11 2024-11-22 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 이를 이용한 방법
CN108690138A (zh) * 2017-04-12 2018-10-23 鸿运华宁（杭州）生物医药有限公司 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
EA201992755A1 (ru) 2017-05-19 2020-04-22 Уси Байолоджикс (Шанхай) Ко. Лтд. Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
JP2020530554A (ja) * 2017-07-20 2020-10-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
KR20200040819A (ko) * 2017-08-16 2020-04-20 브리스톨-마이어스 스큅 컴퍼니 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
EP3697428A4 (en) * 2017-10-20 2021-11-24 President And Fellows Of Harvard College ARTIFICIAL SECRETORS FOR THE PRODUCTION OF HETEROLOGICAL PROTEINS
WO2019107380A1 (ja) * 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
MX2020005160A (es) * 2017-11-28 2020-08-20 Chugai Pharmaceutical Co Ltd Molecula de union a ligando que tiene actividad de union a ligando ajustable.
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
EP3773913A1 (en) 2018-04-11 2021-02-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
JP7460609B2 (ja) 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
US12077577B2 (en) 2018-05-30 2024-09-03 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
WO2019230868A1 (ja) 2018-05-30 2019-12-05 中外製薬株式会社 単ドメイン抗体含有リガンド結合分子
US12195533B2 (en) 2018-07-24 2025-01-14 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TWI863932B (zh) 2018-10-11 2024-12-01 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
JP2022512684A (ja) 2018-10-11 2022-02-07 インヒブルクス インコーポレイテッド Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
US12049505B2 (en) * 2018-12-06 2024-07-30 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
KR20210142594A (ko) 2018-12-26 2021-11-25 시티 오브 호프 활성화 가능한 차폐된 항-ctla4 결합 단백질
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
TW202102270A (zh) 2019-03-21 2021-01-16 美商伊繆諾金公司 製備細胞結合劑-藥物結合物之方法
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
BR112021023735A2 (pt) 2019-06-05 2022-01-04 Chugai Pharmaceutical Co Ltd Molécula de ligação de sítio de clivagem de anti-corpo
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
IL294879A (en) 2020-01-29 2022-09-01 Inhibrx Inc Cd28 single domain antibodies and multivalent and multispecific constructs thereof
AU2021254279A1 (en) 2020-04-09 2022-11-10 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
JP2023520922A (ja) 2020-04-10 2023-05-22 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構築物および関連組成物ならびに方法
WO2021217120A2 (en) * 2020-04-24 2021-10-28 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
US11512113B2 (en) 2020-08-11 2022-11-29 Janux Therapeutics, Inc. Cleavable linker compositions and methods
WO2022125576A1 (en) 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
CA3201115A1 (en) 2020-12-21 2022-06-30 Shanshan LANG Protease-activating cd45-gate car
TW202304958A (zh) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
WO2023034825A1 (en) 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
WO2023060156A2 (en) 2021-10-08 2023-04-13 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
TW202334185A (zh) 2021-10-08 2023-09-01 美商Ｃｙｔｏｍｘ生物製藥公司 可經活化之細胞介素構築體和組合方法
KR20240118749A (ko) 2021-10-15 2024-08-05 싸이톰스 테라퓨틱스, 인크. 활성화 가능한 폴리펩타이드 복합체
IL312145A (en) 2021-10-15 2024-06-01 Amgen Inc An activatable polypeptide complex
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
EP4496816A1 (en) 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
CN119301151A (zh) 2022-03-25 2025-01-10 西托姆克斯治疗公司 可激活双锚定掩蔽分子和其使用方法
WO2024030845A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
TW202424184A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
WO2024030858A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
AR130077A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Substratos escindibles por proteasas, y métodos de uso de los mismos
JP2025538387A (ja) 2022-11-16 2025-11-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ切断可能なリンカーを有する膜結合ｉｌ－１２を含むキメラタンパク質
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
US20250296991A1 (en) 2023-12-01 2025-09-25 Ablynx N.V. Precision activated polypeptides
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200635946A (en) * 2004-12-20 2006-10-16 Abgenix Inc Binding proteins specific for human matriptase
CN101340928A (zh) * 2005-10-21 2009-01-07 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
CN102482347A (zh) * 2009-01-12 2012-05-30 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341A (zh) * 2009-02-23 2012-05-30 希托马克斯医疗有限公司 蛋白原及其使用方法
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1988001513A1 (fr) 1986-08-28 1988-03-10 Teijin Limited Complexe d'anticorps cytocide et procede de production
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
WO1997043423A2 (en) 1996-05-10 1997-11-20 Danisco A/S Alpha-glucuronidases of aspergillus, production thereof and their uses
AUPO930697A0 (en) 1997-09-19 1997-10-09 Walter And Eliza Hall Institute Of Medical Research, The Catalytic antibodies and a method of producing same
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
CA2328422A1 (en) 1998-05-13 1999-11-18 Diversys Limited Selection system
CA2393002A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
WO2002012475A2 (en) * 2000-08-04 2002-02-14 Eli Lilly And Company C1q-related factor, homologous polypeptides and therapeutic uses thereof
ES2368387T5 (es) 2000-10-09 2019-03-07 Cytomx Therapeutics Inc Anticuerpos terapéuticos y que inducen tolerancia
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU2002230630A1 (en) 2000-11-08 2002-05-21 Beth Israel Deaconess Medical Center, Inc. Methods for determining protease cleavage site motifs
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
US7439319B2 (en) 2001-09-14 2008-10-21 Burnham Institute For Medical Research Selective substrates for matrix metalloproteinases
WO2003038083A1 (en) * 2001-10-29 2003-05-08 Bayer Healthcare Ag Regulation of human type i adenylate cyclase
CN101044154A (zh) 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US9079936B2 (en) 2003-07-01 2015-07-14 University Of Maryland, Baltimore Derivatives of APF and methods of use
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
AU2006235276A1 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1919931A4 (en) 2005-08-31 2010-01-20 Univ California CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
MX2009003938A (es) 2006-10-27 2009-04-24 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
AU2010289692A1 (en) 2009-09-02 2012-04-19 Kansas State University Research Foundation MRI and optical assays for proteases
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US20110214205A1 (en) 2010-02-26 2011-09-01 Monsanto Technology Llc. Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
RU2561465C2 (ru) 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины
DK2709667T3 (da) * 2011-05-16 2022-07-04 Tagworks Pharmaceuticals B V Bio-orthogonal lægemiddelaktivering
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
US20130078201A1 (en) 2011-09-28 2013-03-28 Susan Daly Topical sunscreen compositions
PE20150605A1 (es) * 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
BR112014031689A2 (pt) 2012-06-22 2017-07-25 Cytomx Therapeutics Inc anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
WO2014107559A1 (en) 2013-01-03 2014-07-10 Branders.Com, Inc. Methods and apparatus for determining a score value for criteria associated with a gift
JP6605957B2 (ja) 2013-01-04 2019-11-13 シトムクス セラピューティクス，インコーポレイティド 生体系におけるプロテアーゼ活性を検出するための組成物及び方法
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
EA035322B1 (ru) 2013-05-28 2020-05-28 ДиЭсБи-ЮЭсЭй ЛЛК Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP6826055B2 (ja) 2015-03-13 2021-02-03 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法
HK1250037A1 (zh) * 2015-05-04 2018-11-23 Cytomx Therapeutics Inc. 抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法
MY194184A (en) * 2015-05-04 2022-11-17 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
JP7028648B2 (ja) 2015-05-04 2022-03-02 サイトメックス セラピューティクス インコーポレイテッド 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法
US10513558B2 (en) 2015-07-13 2019-12-24 Cytomx Therapeutics, Inc. Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
MY200695A (en) 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
US12049505B2 (en) 2018-12-06 2024-07-30 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200635946A (en) * 2004-12-20 2006-10-16 Abgenix Inc Binding proteins specific for human matriptase
CN101340928A (zh) * 2005-10-21 2009-01-07 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
CN102482347A (zh) * 2009-01-12 2012-05-30 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341A (zh) * 2009-02-23 2012-05-30 希托马克斯医疗有限公司 蛋白原及其使用方法
WO2013192546A1 (en) * 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same

Also Published As

Publication number Publication date
ZA202208159B (en) 2024-11-27
BR112016017649B1 (pt) 2024-01-30
US20190135864A1 (en) 2019-05-09
CN106459153A (zh) 2017-02-22
AU2015210862A1 (en) 2016-08-11
IL294782B1 (en) 2023-06-01
EP4176896A1 (en) 2023-05-10
IL270562A (enExample) 2020-01-30
AU2015210862B2 (en) 2020-04-23
EP4176896B1 (en) 2025-10-08
US11884746B2 (en) 2024-01-30
AU2020205249B2 (en) 2023-09-07
DK3628328T3 (da) 2022-12-05
IL302642B1 (en) 2024-12-01
CN106459153B (zh) 2021-12-21
US9562073B2 (en) 2017-02-07
AU2023278068A1 (en) 2024-01-04
KR102466591B1 (ko) 2022-11-14
IL246988A0 (en) 2016-09-29
WO2015116933A3 (en) 2015-10-08
ES2932777T3 (es) 2023-01-25
RU2016135239A (ru) 2018-03-12
NZ722401A (en) 2023-06-30
BR112016017649A2 (pt) 2017-10-10
JP2023159314A (ja) 2023-10-31
US10138272B2 (en) 2018-11-27
IL294782B2 (en) 2023-10-01
RU2016135239A3 (enExample) 2019-01-17
JP2021072848A (ja) 2021-05-13
IL294782A (en) 2022-09-01
IL317045A (en) 2025-01-01
KR20160113717A (ko) 2016-09-30
CA2937370A1 (en) 2015-08-06
EP3628328B1 (en) 2022-09-14
JP7337864B2 (ja) 2023-09-04
US20170204139A1 (en) 2017-07-20
CN114106099A (zh) 2022-03-01
US20150218217A1 (en) 2015-08-06
IL270562B (en) 2022-08-01
WO2015116933A2 (en) 2015-08-06
EP3099319A2 (en) 2016-12-07
US11028126B2 (en) 2021-06-08
IL302642B2 (en) 2025-04-01
JP6835586B2 (ja) 2021-02-24
US20220411470A1 (en) 2022-12-29
IL302642A (en) 2023-07-01
JP2017509594A (ja) 2017-04-06
EP3628328A1 (en) 2020-04-01
US20240150402A1 (en) 2024-05-09
BR122023022856A2 (pt) 2023-12-12
AU2020205249A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
CN114106099B (zh) 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
AU2020203910B2 (en) Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
CN113271956A (zh) 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法
HK40093216A (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2937370C (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
HK40023271B (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
HK40023271A (en) Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant